Brief: Cytomed Therapeutics Refutes "Misleading" Claims & Reaffirms Clinical Progress
28/01/2026 16:04
Jan 28 (Reuters) - CytoMed Therapeutics Ltd F98.F: CYTOMED THERAPEUTICS- DOES NOT CLAIM THERAPEUTIC CANDIDATES ARE APPROVED FOR COMMERCIAL USE OR CLINICALLY VALIDATED BEYOND CURRENT DEVELOPMENT STAGE CYTOMED THERAPEUTICS- REFUTES "MISLEADING" CLAIMS REGARDING RESEARCH PROGRAMS, CLINICAL PROGRESS, OPERATIONS & REAFFIRMS CLINICAL PROGRESS Source text: ID:nGNX7LzvkW Further company coverage: F98.F ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on CytoMed Therapeutics
See all newsBrief: Cytomed Therapeutics Limited Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brief: Cytomed Therapeutics Refutes "Misleading" Claims & Reaffirms Clinical Progress
Brief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025
Brief: Cytomed Therapeutics Ltd Files For Mixed Shelf Of Up To $50 Million